Recent research have centered on the convergence of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopaminergic communication. While GLP stimulators are widely employed for managing type 2 diabetes mellitus, their emerging impacts on reward circuits, specifically mediated by dopamine pathways, are receiving significant interest